{"id":28776,"date":"2023-04-11T11:00:47","date_gmt":"2023-04-11T11:00:47","guid":{"rendered":"https:\/\/news.cancerresearchuk.org\/?p=25536"},"modified":"2024-11-03T15:12:48","modified_gmt":"2024-11-03T15:12:48","slug":"olaparib-approved-for-800-prostate-and-breast-cancer-patients-in-england","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/olaparib-approved-for-800-prostate-and-breast-cancer-patients-in-england\/","title":{"rendered":"Olaparib approved for 800 prostate and breast cancer patients in England"},"content":{"rendered":"
\"BreastBreast cancer cells <\/p>\n

” data-medium-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/05\/Untitled-620-x-348-px-300×168.jpg” data-large-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/05\/Untitled-620-x-348-px.jpg”><\/p>\n

Breast cancer cells Credit: NCI <\/span><\/p>\n<\/div>\n

Olaparib (Lynparza)<\/span><\/a>, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain <\/span>breast cancers<\/span><\/a> and <\/span>prostate cancers<\/span><\/a> in England.<\/span> <\/span><\/p>\n

The decision came after NHS England negotiated a discount for the drug from its manufacturer, AstraZeneca. <\/span> <\/span><\/p>\n

Previously, the National Institute for Health and Care Excellence (NICE), had not recommended olaparib as a treatment for certain types of breast or prostate cancer because of concerns about its cost-effectiveness. <\/span> <\/span><\/p>\n

Now, though, the drug will be made available through the NHS for more patients with inherited mutations in DNA repair genes called <\/span>BRCA genes<\/span><\/a>. These faults raise the risk of certain cancers, but they can also be targeted with olaparib.<\/span> <\/span><\/p>\n

NICE estimates that 300 adults with breast cancer will now be eligible for treatment with the drug, as will around 500 more people with advanced prostate cancer.<\/span> <\/span><\/p>\n

\u201cCancer Research UK-funded scientists played a leading role in the development and testing of olaparib, so this news is really exciting to see,\u201d said Martin Ledwick, our chief information nurse. <\/span> <\/span><\/p>\n

\u201cThe evidence shows that these drugs mean better chances of a good outcome for patients with early-stage breast cancer and advanced prostate cancer related to BRCA gene mutations. <\/span> <\/span><\/p>\n

\u201cWe hope that today\u2019s news will give patients facing these forms of cancer better options for treatment, to give them more time to make memories with the people they love.\u201d<\/span> <\/span><\/p>\n

Who is olaparib now recommended for?<\/h2>\n

NICE had already recommended olaparib for some BRCA-linked <\/span>ovarian cancers<\/span><\/a> that have come back or continued growing after treatment. It is now being made available on the NHS for two extra patient groups with faults in BRCA genes:<\/span> <\/span><\/p>\n